Journal of the American Society of Nephrology
2007 JASN IMPACT FACTOR 7.111 HOME   AUTHOR INFO   EDITORIAL BOARD   SUBSCRIBE   FEEDBACK   ALERTS   HELP 
    advanced
CURRENT ISSUE ARCHIVES JASN Express ONLINE SUBMISSION


J Am Soc Nephrol 15: 2619-2629, 2004
© 2004 American Society of Nephrology
doi: 10.1097/01.ASN.0000139066.77892.04

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kelly, D. J.
Right arrow Articles by Gilbert, R. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kelly, D. J.
Right arrow Articles by Gilbert, R. E.

BASIC SCIENCE

Tranilast Attenuates Structural and Functional Aspects of Renal Injury in the Remnant Kidney Model

Darren J. Kelly, Yuan Zhang, Renae Gow and Richard E. Gilbert

University of Melbourne Departments of Medicine, St. Vincent’s Hospital, Victoria, Australia

Correspondence to Darren J. Kelly, Department of Medicine, St. Vincent’s Hospital, Fitzroy, Victoria, 3065, Australia. Phone: +61-3-9288-2580; Fax: +61-3-9288-2581; E-mail: dkelly{at}medstv.unimelb.edu.au

Pathologic fibrosis is a key feature of progressive renal disease that correlates closely with kidney dysfunction and in which the prosclerotic growth factor TGF-{beta} has been consistently implicated. Tranilast (n-[3,4-dimethoxycinnamoyl] anthranilic acid), an antifibrotic agent that is used to treat hypertrophic scars and scleroderma, has also been shown to inhibit TGF-{beta}–induced extracellular matrix synthesis in a range of cell types, including those of renal origin. Therefore, the effects of tranilast on kidney fibrosis and dysfunction were examined in the subtotal nephrectomy model of progressive renal injury. Subtotal nephrectomy led to proteinuria and renal dysfunction in association with glomerulosclerosis, tubulointerstitial fibrosis, and macrophage accumulation. Despite persistent hypertension, treatment with tranilast led to a reduction in albuminuria (61.7 x 1.2 versus 20.5 x/÷ 1.3 mg/d; P < 0.01) and plasma creatinine (0.16 versus 0.08 mmol/L; P < 0.01) in subtotally nephrectomized rats. In addition, features suggestive of TGF-{beta} activation, including glomerulosclerosis, tubulointerstitial fibrosis, tubular atrophy, and macrophage accumulation, all were significantly attenuated by tranilast in association with evidence of reduced TGF-{beta} signaling in vivo. In the context of a recent pilot study in humans, the findings of the present report suggest that tranilast may provide a novel strategy for the treatment of progressive kidney disease characterized by fibrotic scarring.




This article has been cited by other articles:


Home page
Nephrol Dial TransplantHome page
P. Boor, K. Sebekova, T. Ostendorf, and J. Floege
Treatment targets in renal fibrosis
Nephrol. Dial. Transplant., December 1, 2007; 22(12): 3391 - 3407.
[Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
D. J. Kelly, Y. Zhang, K. Connelly, A. J. Cox, J. Martin, H. Krum, and R. E. Gilbert
Tranilast attenuates diastolic dysfunction and structural injury in experimental diabetic cardiomyopathy
Am J Physiol Heart Circ Physiol, November 1, 2007; 293(5): H2860 - H2869.
[Abstract] [Full Text] [PDF]


Home page
Journal of Renin-Angiotensin-Aldosterone SystemHome page
I. Tsunenari, T. Ohmura, R. Seidler, M. Chachin, T. Hayashi, A. Konomi, T. Matsumaru, T. Sumida, N. Hayashi, and Y. Horie
Renoprotective effects of telmisartan in the 5/6 nephrectomised rats
Journal of Renin-Angiotensin-Aldosterone System, June 1, 2007; 8(2): 93 - 100.
[Abstract] [PDF]


Home page
GutHome page
N. Oshitani, H. Yamagami, K. Watanabe, K. Higuchi, and T. Arakawa
Long-term prospective pilot study with tranilast for the prevention of stricture progression in patients with Crohn's disease
Gut, April 1, 2007; 56(4): 599 - 600.
[Full Text] [PDF]


Home page
Nephrol Dial TransplantHome page
J. Soma, K. Sato, H. Saito, and Y. Tsuchiya
Effect of tranilast in early-stage diabetic nephropathy
Nephrol. Dial. Transplant., October 1, 2006; 21(10): 2795 - 2799.
[Abstract] [Full Text] [PDF]


Home page
CJASNHome page
R. E. Gilbert, K. Connelly, D. J. Kelly, C. A. Pollock, and H. Krum
Heart Failure and Nephropathy: Catastrophic and Interrelated Complications of Diabetes
Clin. J. Am. Soc. Nephrol., March 1, 2006; 1(2): 193 - 208.
[Abstract] [Full Text] [PDF]




HOME CURRENT ISSUE ARCHIVES JASN Express ONLINE SUBMISSION AUTHOR INFO
EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP